Alnylam Pharmaceuticals (ALNY) Price Target Raised to $86.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price raised by research analysts at Nomura to $86.00 in a research report issued on Friday. The firm presently has a “sell” rating on the biopharmaceutical company’s stock. Nomura’s price objective indicates a potential downside of 25.81% from the company’s previous close.

A number of other research firms have also weighed in on ALNY. Morgan Stanley lifted their price objective on shares of Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the company an “equal weight” rating in a research report on Thursday, November 9th. Cowen reiterated a “buy” rating and issued a $151.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 9th. Credit Suisse Group lifted their price objective on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a research report on Friday, November 3rd. Leerink Swann lifted their price objective on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the company a “market perform” rating in a research report on Thursday, January 25th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $152.00 price objective (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $125.85.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down $0.40 during trading on Friday, hitting $115.92. 1,304,954 shares of the stock were exchanged, compared to its average volume of 887,777. The firm has a market cap of $11,400.00, a PE ratio of -22.08 and a beta of 2.68. Alnylam Pharmaceuticals has a fifty-two week low of $40.93 and a fifty-two week high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $37.90 million during the quarter, compared to analyst estimates of $19.31 million. During the same period in the previous year, the firm earned ($1.32) earnings per share. The business’s revenue was up 116.6% compared to the same quarter last year. equities analysts expect that Alnylam Pharmaceuticals will post -5.29 EPS for the current year.

In related news, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $135.89, for a total value of $4,076,700.00. Following the sale, the senior vice president now directly owns 41,500 shares in the company, valued at approximately $5,639,435. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the completion of the sale, the chief executive officer now owns 223,710 shares in the company, valued at $28,379,850.60. The disclosure for this sale can be found here. Insiders sold a total of 220,409 shares of company stock worth $28,667,017 over the last quarter. Insiders own 4.30% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $141,000. CENTRAL TRUST Co boosted its position in shares of Alnylam Pharmaceuticals by 746.3% in the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,000 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $165,000. QS Investors LLC boosted its position in shares of Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 900 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 167 shares in the last quarter. Institutional investors and hedge funds own 88.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals (ALNY) Price Target Raised to $86.00” was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.com-unik.info/2018/02/09/alnylam-pharmaceuticals-alny-price-target-raised-to-86-00.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit